Clinical Trial

Development of Cognitive Assessment Tools in Parkinson Disease

Clinical Scales, Cognitive Symptoms
Institute for Neurodegenerative Disorders
Parkinson Disease
Radiation
[123I] IBVM and SPECT imaging

The main objectives of this protocol are as follows: 1. To assess the sensitivity and specificity of ANAM-PD in detecting cognitive status in patients with Parkinson disease (PD) and healthy controls (HC). 2. To validate the specific individual domains of the ANAM-PD cognitive battery by comparisons to available standardized cognitive evaluation scales administered to the patients with Parkinson disease with and healthy control subjects. 3. To evaluate the reliability of the ANAM-PD battery of tests by comparing repeated administrations of the ANAM-PD battery on a sub-set of subjects with Parkinson disease and healthy controls. 4. To characterize cholinergic neurotransmission through imaging the vesicular acetylcholine transporter binding with 123Iodobenzovesamicol (IBVM) and SPECT in PD patients and healthy controls.

Link to the current ClinicalTrials.gov record.
Agency: 
Institute for Neurodegenerative Disorders
Phase: 
N/A
Study Design: 
Screening, Non-Randomized, Open Label, Parallel Assignment, Efficacy Study
Condition: 
Parkinson Disease
Intervention type: 
Radiation
Intervention Name: 
[123I] IBVM and SPECT imaging
Information Retrieved from Source: 
Wednesday, 29 October 2008
Reference: 
Kabat MH, Kane RL, Jefferson AL, DiPino RK. Construct validity of selected Automated Neuropsychological Assessment Metrics (ANAM) battery measures. The Clinical neuropsychologist. 2001;15(4):498-507.
Reply